No Data
Is CanSino Biologics (HKG:6185) A Risky Investment?
CanSino Biologics Gets Registration Certificate for Meningitis Vaccine in Indonesia
CanSino Biologics Expands Global Reach With Indonesian Vaccine Approval
CANSINOBIO (06185.HK): Manhaixin has obtained the registration certificate from Indonesia.
On December 30, Gelonghui reported that CANSINOBIO (06185.HK) announced that its ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 carrier) ("MCV4", trade name: Manhaixin) has obtained the registration certificate granted by the Indonesia Food and Drug Authority. The company's MCV4 is suitable for infants aged 3 months to 3 years (47 months), and vaccination with MCV4 can stimulate the body to produce immunity against the ACYW135 group Neisseria meningitidis for the prevention of epidemic meningitis caused by ACYW135 group Neisseria meningitidis, and is being developed domestically.
Express News | CanSino Biologics Inc - Menhycia Obtains Drug Registration Certificate in Indonesia
CanSino Biologics Inc. (688185.SH): MCV4 Manhaixin has obtained a registration certificate in Indonesia.
CanSino Biologics Inc. (688185.SH) announced that the company's ACYW135 group meningococcal polysaccharide conjugate vaccine (...)
CanSino Biologics Inc. (HKG:6185) Analysts Are Reducing Their Forecasts For Next Year
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
